Mosby's 2014 Nursing Drug Reference (387 page)

BOOK: Mosby's 2014 Nursing Drug Reference
12.93Mb size Format: txt, pdf, ePub

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

terbinafine topical

 

terbutaline (Rx)

(ter-byoo′ta-leen)

Bricanyl

Func. class.:
Selective β
2
-agonist; bronchodilator

Chem. class.:
Catecholamine

Do not confuse:
terbutaline
/TOLBUTamide/terbinafine

ACTION:

Relaxes bronchial smooth muscle by direct action on β
2
-adrenergic receptors through the accumulation of cAMP at β-adrenergic receptor sites; bronchodilation, diuresis, CNS, cardiac stimulation occur; relaxes uterine smooth muscle

USES:

Bronchospasm

Unlabeled uses:
Premature labor, nonresponsive status asthmaticus in children (IV)

CONTRAINDICATIONS:

Hypersensitivity to sympathomimetics, closed-angle glaucoma, tachydysrhythmias

Precautions:
Pregnancy (B), breastfeeding, geriatric patients, cardiac disor
ders, hyperthyroidism, diabetes mellitus, prostatic hypertension, hypertension, seizure disorder

 

Black Box Warning:

Labor

DOSAGE AND ROUTES
Calculator
Bronchospasm

• Adult and child >12 yr:
PO
2.5-5 mg q8hr;
SUBCUT
0.25 mg q15-30min, max 0.5 mg in 4 hr

• Adolescent ≤15 yr and child ≥12 yr:
PO
2.5 mg tid, max 7.5 mg/day

• Child 6-11 yr (unlabeled):
PO
0.05 mg/kg q8hr, may increase slowly

Renal dose

• Adult:
PO
CCr 10-50 ml/min, 50% of dose; CCr <10 ml/min, avoid use

Tocolytic (preterm labor) (unlabeled)

• Adult:
SUBCUT
0.25 mg q20min to 6 hr, hold if pulse >120 bpm

Available forms:
Tabs 2.5, 5 mg; inj 1 mg/ml

Administer:

• 
With food; may be crushed

• 
2 hr before bedtime to avoid sleeplessness

IV route (unlabeled)

• 
Only used if subcut is ineffective

• 
IV after diluting each 5 mg/1 L D
5
W for inf

• 
IV, run 5 mcg/min; may increase 5 mcg q10min, titrate to response; after 1/2-1 hr, taper dose by 5 mcg; switch to PO as soon as possible

Y-site compatibilities:
Insulin (regular)

SIDE EFFECTS

CNS:
Tremors, anxiety, insomnia, headache, dizziness, stimulation

CV:
Palpitations, tachycardia, hypertension, dysrhythmias,
cardiac arrest, QT prolongation

GI:
Nausea, vomiting

META:
Hypokalemia, hyperglycemia

RESP:
Paradoxical bronchospasm, dyspnea

PHARMACOKINETICS

PO:
Onset 1/2 hr, peak 1-2 hr, duration 4-8 hr, half-life 3.4 hr

SUBCUT:
Onset 6-15 min, peak 1/2-1 hr, duration 1½-4 hr, half-life 5.7 hr

INTERACTIONS

• 
Hypertensive crisis: MAOIs

Increase:
effects of both products—other sympathomimetics

Decrease:
action—β-blockers; do not use together

Drug/Herb

Increase:
effect—green tea (large amounts), guarana

NURSING CONSIDERATIONS
Assess:

• 
Respiratory function: vital capacity, forced expiratory volume, ABGs, B/P, pulse, respiratory pattern, lung sounds, sputum before and after treatment

• 
Tolerance in patients receiving long-term therapy; dose may have to be changed; monitor for rebound bronchospasm

 
Paradoxical bronchospasm:
dyspnea, wheezing; keep emergency equipment nearby

• 
Labor:
maternal heart rate, B/P, contraction, fetal heart rate; can inhibit uterine contractions, labor; monitor for hypoglycemia

Perform/provide:

• 
Storage at room temp; do not use discolored sol

• 
Increase in fluids of >2 L/day

Evaluate:

• 
Therapeutic response: absence of dyspnea, wheezing

Teach patient/family:

• 
Not to use OTC medications because extra stimulation may occur

• 
About all aspects of product; to avoid smoking, smoke-filled rooms, persons with respiratory infections

• 
To increase fluids by >2 L/day; to allow 15 min between inhalation of product and inhaled product containing steroid

• 
To take on time; if missed, not to make up after 1 hr, to wait until next dose

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

terconazole vaginal
antifungal

 

teriparatide (Rx)

(tah-ree-par′ah-tide)

Forteo

Func. class.:
Parathyroid hormone (rDNA)

Chem. class.:
Teriparatide

ACTION:

Contains human recombinant parathyroid hormone to stimulate new bone growth

USES:

Postmenopausal women with osteoporosis, men with primary or hypogonadal osteoporosis who are at high risk for fracture, glucocorticoid-induced osteoporosis

Unlabeled uses:
Hypoparathyroidism

CONTRAINDICATIONS:

Hypersensitivity, increased baseline risk for osteosarcoma (Paget’s disease, open epiphyses; previous bone radiation), bone metastases, history of skeletal malignancies, other metabolic bone diseases, preexisting hypercalcemia

Precautions:
Pregnancy (C), breastfeeding, children, urolithiasis, hypotension, use >2 yr, cardiac disease

 

Black Box Warning:

Secondary malignancy

DOSAGE AND ROUTES
Calculator

• Adult:
SUBCUT
20 mcg/day up to 2 yr (osteoporosis); long-term/lifetime use is recommended (glucocorticoid-induced osteoporosis)

Available forms:
Prefilled pen delivery device (delivers 20 mcg/day)

Administer:
SUBCUT route

• 
Give by SUBCUT using disposable pen only; inject in thigh or abdomen; lightly pinch fold of skin; insert needle; release skin; inject at 90-degree angle over 5 sec; rotate inj sites

• 
Have patient sit or lie down; orthostatic hypotension may occur

• 
Protect from freezing, light; refrigerate pen

SIDE EFFECTS

CNS:
Dizziness, headache, insomnia, depression, vertigo

CV:
Hypertension, angina, syncope

GI:
Nausea, diarrhea, dyspepsia, vomiting, constipation

INTEG:
Rash, sweating

MISC:
Pain, asthenia, hyperuricemia

MS:
Arthralgia, leg cramps, back/leg pain, weakness,
osteosarcoma (rare)

RESP:
Rhinitis, cough, pharyngitis, pneumonia, dyspnea

PHARMACOKINETICS

SUBCUT:
Extensively and rapidly absorbed, metabolized by liver, excreted by kidneys, terminal half-life 1 hr, onset rapid, peak 1/2 hr, duration 3 hr

INTERACTIONS

Increase:
digoxin toxicity: digoxin

Drug/Lab Test

Increase:
calcium, uric acid, urinary calcium

Decrease:
phosphorous, magnesium

NURSING CONSIDERATIONS
Assess:

 

Black Box Warning:

Secondary malignancy: osteosarcoma, dependent on length of treatment; those at higher risk for osteosarcoma should not use this product

• 
Uric acid, magnesium, creatinine, BUN, urine pH, vit D, phosphate for normal serum levels; serum calcium may be transiently increased after dosing (max at 4-6 hr after dose)

• 
Bone pain, headache, fatigue, changes in LOC, leg cramps

• 
Signs of persistent hypercalcemia:
nausea, vomiting, constipation, lethargy, muscle weakness

• 
Nutritional status: diet for sources of vit D (milk, some seafood), calcium (dairy products, dark green vegetables), phosphates (dairy products)

Perform/provide:

• 
Store refrigerated, do not freeze; may be used for 28 days after first inj

Evaluate:

• 
Therapeutic response: increased bone mineral density

Teach patient/family:

• 
About the symptoms of hypercalcemia

• 
About foods rich in calcium, vit D

• 
How to use delivery device, dispose of needles; not to share pen with others, to use at same time of day

• 
To sit or lie down if dizziness or fast heartbeat occurs after 1st few doses

• 
To rotate administration sites

• 
To store pen in refrigerator, pen may be used for 28 days

Other books

An Educated Death by Kate Flora
First Strike by Craig Simpson
Flash of Fire by M. L. Buchman
Two Brothers by Ben Elton
Carla Kelly by Reforming Lord Ragsdale
Garden Spells by Sarah Addison Allen
Danger Woman by Frederick Ramsay
Silent Valley by Malla Nunn
In Real Life by Chris Killen